Bellicum Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Bellicum Pharmaceuticals şirketinin toplam hissedar öz sermayesi $4.6M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $6.9M ve $2.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$5.91m
Eşitlik	US$4.60m
Toplam yükümlülükler	US$2.25m
Toplam varlıklar	US$6.85m

Son finansal sağlık güncellemeleri

Recent updates

Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56

Aug 11

Bellicum launches $25M underwritten offering

Oct 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BLCM 'nin kısa vadeli varlıkları ( $6.8M ) kısa vadeli yükümlülüklerini ( $2.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: BLCM un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BLCM borçsuzdur.

Borcun Azaltılması: BLCM şirketinin 5 yıl önce borç/öz sermaye oranı 38.5% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BLCM şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 23.6 oranında tarihsel oranda büyümeye devam ederse BLCM un bir yıldan az nakit akışı süresi vardır.

Bellicum Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Bellicum Pharmaceuticals Files Form 15

Nasdaq to Delist the Common Stock of Bellicum Pharmaceuticals

Bellicum Pharmaceuticals Receives Written Notification from Nasdaq Regarding Listing Rule 5550(b)(1)

Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

Recent updates

Bellicum Pharmaceuticals Files Form 15

The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM).

Nasdaq to Delist the Common Stock of Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from NASDAQ Composite Index

Bellicum Pharmaceuticals Receives Written Notification from Nasdaq Regarding Listing Rule 5550(b)(1)

Consensus EPS estimates fall by 39%

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer At ASCO GU Cancers Symposium

Bellicum Pharmaceuticals, Inc. Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

Price target decreased to US$5.00

Insufficient new directors

Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56

Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$5.00

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Announces Board Changes

Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Provides an Operational Update

Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)

Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020

Bellicum Pharmaceuticals, Inc. Announces First Report Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

New 90-day high: US$4.65

Price target lowered to US$4.50

Bellicum Pharmaceuticals, Inc. Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell 2000 Dynamic Index

Bellicum Pharmaceuticals, Inc. Announces Resignation of David Strauss as Senior Director, Corporate Controller, and as the Company’s Principal Accounting Officer, Effective January 22, 2021

Bellicum Pharmaceuticals, Inc. Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

Bellicum Pharmaceuticals, Inc. Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc. to Reduce Staff by 2020

Bellicum launches $25M underwritten offering

Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019

New 90-day low - US$6.28

Earnings released

The University of Texas MD Anderson Cancer Center completed the acquisition of certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM).

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell Microcap Value Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin